Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CBX7 | O95931 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13479500 | 0.84 | HTT (0.56) | ALDH1A1LMNAPOLBHTTHPGD | |
| SCHEMBL14511721 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAPOLBHTTGAA | |
| SCHEMBL10522334 | 0.82 | L3MBTL1 (0.56) | ALDH1A1LMNAHRH4POLBHTT | |
| SCHEMBL24510724 | 0.82 | ALDH1A1 (0.52) | ALDH1A1LMNAPOLBHTTL3MBTL1 | |
| SCHEMBL2033421 | 0.82 | L3MBTL1 (0.64) | ALDH1A1LMNAHRH4POLBHTT | |
| SCHEMBL14100520 | 0.81 | L3MBTL1 (0.59) | ALDH1A1LMNAPOLBHTTL3MBTL1 | |
| SCHEMBL3881407 | 0.81 | L3MBTL1 (0.55) | ALDH1A1LMNAHRH4POLBL3MBTL1 | |
| SCHEMBL2378330 | 0.81 | L3MBTL1 (0.55) | ALDH1A1LMNAHRH4POLBHTT | |
| SCHEMBL16982493 | 0.81 | TP53 (0.48) | ALDH1A1LMNAHRH4POLBL3MBTL1 | |
| SCHEMBL14511327 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624126-A | Selective tyrosine kinase 2 (TYK 2) inhibitor compound, synthesis method and application | 中国药科大学 | 2024-03-01 | — | — | CN | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | ALDH1A1 779/4885LMNA 3783/4885HRH4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.